Teclistamab plus immune cells for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your multiple myeloma has come back or is not responding to treatment.
- You have had 1 or 2 prior treatment lines (a stem cell transplant counts as part of one line).
- You have tried at least one IMiD (like lenalidomide), one proteasome inhibitor (like bortezomib), and one anti-CD38 antibody (like daratumumab).
- Your disease is actively progressing and measurable (by blood or urine tests).
- You have not had a prior stem cell transplant from a donor, and no BCMA-directed therapy before.
- Your kidney and liver function are adequate, and blood counts are above certain minimums.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
This study tests how well teclistamab works for people with multiple myeloma that has come back or not responded to at least three prior treatments. You may be eligible if you are starting teclistamab as part of your regular care.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests a combination of two drugs, teclistamab and pomalidomide, given in an alternating schedule to see if it helps people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to improve outcomes with manageable side effects.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests a combination of immunotherapy drugs for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this approach can better control the disease.
Hear when a new Multiple Myleoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.